Clinical Trial Update: A Study of Prometic Plasminogen IV Infusion in Subjects With Hypoplasminogenemia [Phase 2, Phase 3]

View source ↗

Summary

Phase 2/3 clinical trial of Prometic plasminogen IV infusion in hypoplasminogenemia and congenital plasminogen deficiency has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Congenital Plasminogen Deficiency
• Hypoplasminogenemia

Drugs mentioned

• Prometic plasminogen IV infusion (plasminogen IV infusion)

Snippet

Sponsor: Prometic Biotherapeutics, Inc. | Conditions: Hypoplasminogenemia, Congenital Plasminogen Deficiency | Phase 2, Phase 3 | Status: COMPLETED | Results posted: 2021-04-19